Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins

References

• Taylor SW, Fahy E, Zhang B, et al. Characterization of the human heart mitochondrial proteome. J Proteome Res. 2003;21(3):281–286.
   Google Scholar
• Zorzano A, Claret M. Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction. Front Aging Neurosci. 2015;7:101.
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–795.
   PubMed Web of Science ®Google Scholar
• Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008;134(1):112–123.
   PubMed Web of Science ®Google Scholar
• Meisinger C, Sickmann A, Pfanner N. The mitochondrial proteome: from inventory to function. Cell. 2008;134(1):22–24.
   PubMed Web of Science ®Google Scholar
• Foster LJ, De Hoog CL, Zhang Y, et al. A mammalian organelle map by protein correlation profiling. Cell. 2006;125(1):187–199.
   PubMed Web of Science ®Google Scholar
• Vieira HLA, Haouzi D, El Hamel C, et al. Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ. 2000;7(12):1146–1154.
   PubMed Web of Science ®Google Scholar
• Yogev O, Pines O. Dual targeting of mitochondrial proteins: mechanism, regulation and function. Biochim Biophys Acta. 2011;1808(3):1012–1020.
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422(6928):198–207.
   PubMed Web of Science ®Google Scholar
• Andersen JS, Wilkinson CJ, Mayor T, et al. Proteomic characterization of the human centrosome by protein correlation profiling. Nature. 2003;426(6966):570–574.
   PubMed Web of Science ®Google Scholar
• Kumar A. Subcellular localization of the yeast proteome. Genes Dev. 2002;16(6):707–719.
   PubMed Web of Science ®Google Scholar
• Luo X, Budihardjo I, Zou H, et al. A Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94(4):481–490.
   PubMed Web of Science ®Google Scholar
• Gabaldón T, Rainey D, Huynen MA. Tracing the evolution of a large protein complex in the eukaryotes, NADH: ubiquinone oxidoreductase (Complex I). J Mol Biol. 2005;348(4):857–870.
   PubMed Web of Science ®Google Scholar
• Hiltunen JK, Schonauer MS, Autio KJ, et al. Mitochondrial fatty acid synthesis type II: more than just fatty acids. J Biol Chem. 2009;284(14):9011–9015.
   PubMed Web of Science ®Google Scholar
• Nilsson R, Schultz IJ, Pierce EL, et al. Discovery of Genes Essential for Heme Biosynthesis through large-scale gene expression analysis. Cell Metab. 2009;10(2):119–130.
   PubMed Web of Science ®Google Scholar
• Anderson KA, Hirschey MD. Mitochondrial protein acetylation regulates metabolism. Essays Biochem. 2012;52:23–35.
   PubMed Web of Science ®Google Scholar
• Palmieri EM, Spera I, Menga A, et al. Acetylation of human mitochondrial citrate carrier modulates mitochondrial citrate/malate exchange activity to sustain NADPH production during macrophage activation. Biochim Biophys Acta. 2015;1847(8):729–738.
   PubMed Web of Science ®Google Scholar
• D’Erchia AM, Atlante A, Gadaleta G, et al. Tissue-specific mtDNA abundance from exome data and its correlation with mitochondrial transcription, mass and respiratory activity. Mitochondrion. 2015;20:13–21.
   PubMed Web of Science ®Google Scholar
• Kelly RDW, Mahmud A, McKenzie M, et al. Mitochondrial DNA copy number is regulated in a tissue specific manner by DNA methylation of the nuclear-encoded DNA polymerase gamma A. Nucleic Acids Res. 2012;40(20):10124–10138.
   PubMed Web of Science ®Google Scholar
• Facucho-Oliveira JM, Alderson J, Spikings EC, et al. Mitochondrial DNA replication during differentiation of murine embryonic stem cells. J Cell Sci. 2007;120(Pt 22):4025–4034.
   PubMed Web of Science ®Google Scholar
• Folmes CDL, Dzeja PP, Nelson TJ, et al. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell. 2012;11(5):596–606.
   PubMed Web of Science ®Google Scholar
• Cooper O, Seo H, Andrabi S. et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med. 2012;4(141):141ra90.
   PubMed Web of Science ®Google Scholar
• Xu X, Duan S, Yi F, et al. Mitochondrial regulation in pluripotent stem cells. Cell Metab. 2013;18(3):325–332.
   PubMed Web of Science ®Google Scholar
• Mootha VK, Bunkenborg J, J V O, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell. 2003;115(5):629–640.
   PubMed Web of Science ®Google Scholar
• Capaldi RA, Halphen DG, Zhang Y-Z, et al. Complexity and tissue specificity of the mitochondrial respiratory chain. J Bioenerg Biomembr. 1988;20(3):291–311.
   PubMed Web of Science ®Google Scholar
• Kuhn-Nentwig L, Kadenbach B. Isolation and properties of cytochrome c oxidase from rat liver and quantification of immunological differences between isozymes from various rat tissues with subunit-specific antisera. Eur J Biochem. 1985;149(1):147–158.
   PubMedGoogle Scholar
• Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet. 2010;11:25–44.
   PubMed Web of Science ®Google Scholar
• Cho D-H, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci. 2010;67(20):3435–3447.
   PubMed Web of Science ®Google Scholar
• Gerdes F, Tatsuta T, Langer T. Mitochondrial AAA proteases–towards a molecular understanding of membrane-bound proteolytic machines. Biochim Biophys Acta. 2012;1823(1):49–55.
   PubMed Web of Science ®Google Scholar
• Khalimonchuk O, Jeong M-Y, Watts T, et al. Selective Oma1 protease-mediated proteolysis of Cox1 subunit of cytochrome oxidase in assembly mutants. J Biol Chem. 2012;287(10):7289–7300.
   PubMed Web of Science ®Google Scholar
• Bouman L, Schlierf A, Lutz AK, et al. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ. 2011;18(5):769–782.
   PubMed Web of Science ®Google Scholar
• Campello S, Strappazzon F, Cecconi F. Mitochondrial dismissal in mammals, from protein degradation to mitophagy. Biochim Biophys Acta. 2014;1837(4):451–460.
   PubMed Web of Science ®Google Scholar
• Bach D, Pich S, Soriano FX, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 2003;278(19):17190–17197.
   PubMed Web of Science ®Google Scholar
• Bossy-Wetzel E, Barsoum MJ, Godzik A, et al. Mitochondrial fission in apoptosis, neurodegeneration and aging. Curr Opin Cell Biol. 2003;15(6):706–716.
   PubMed Web of Science ®Google Scholar
• Liu H, Nakagawa T, Kanematsu T, et al. Isolation of 10 differentially expressed cDNAs in differentiated neuro2a cells induced through controlled expression of the GD3 synthase gene. J Neurochem. 2008;72(5):1781–1790.
   Google Scholar
• Niemann A, Ruegg M, La Padula V, et al. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol. 2005;170(7):1067–1078.
   PubMed Web of Science ®Google Scholar
• Kramer T, Enquist LW. Alphaherpesvirus infection disrupts mitochondrial transport in neurons. Cell Host & Microbe. 2012;11(5):504–514.
   PubMed Web of Science ®Google Scholar
• Genova ML, Lenaz G. Functional role of mitochondrial respiratory supercomplexes. Biochim Biophys Acta. 2014;1837(4):427–443.
   PubMed Web of Science ®Google Scholar
• Chacinska A, van der Laan M, Mehnert CS, et al. Distinct forms of mitochondrial TOM-TIM supercomplexes define signal-dependent states of preprotein sorting. Mol Cell Biol. 2010;30(1):307–318.
   PubMed Web of Science ®Google Scholar
• Chacinska A, Koehler CM, Milenkovic D, et al. Importing mitochondrial proteins: machineries and mechanisms. Cell. 2009;138(4):628–644.
   PubMed Web of Science ®Google Scholar
• Baseler WA, Dabkowski ER, Williamson CL, et al. Proteomic alterations of distinct mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import dysfunction. Am J Physiol Regul Integr Comp Physiol. 2011;300(2):R186–200.
   PubMed Web of Science ®Google Scholar
• Rabilloud T, Kieffer S, Procaccio V, et al. Two-dimensional electrophoresis of human placental mitochondria and protein identification by mass spectrometry: toward a human mitochondrial proteome. Electrophoresis. 1998;19(6):1006–1014.
   PubMed Web of Science ®Google Scholar
• Schwartz R, Ting CS, King J. Whole proteome pI values correlate with subcellular localizations of proteins for organisms within the three domains of life. Genome Res. 2001;11(5):703–709.
   PubMed Web of Science ®Google Scholar
• Ozawa T, Sako Y, Sato M, et al. A genetic approach to identifying mitochondrial proteins. Nat Biotechnol. 2003;21(3):287–293.
   PubMed Web of Science ®Google Scholar
• Kislinger T, Cox B, Kannan A, et al. Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell. 2006;125(1):173–186.
   PubMed Web of Science ®Google Scholar
• Smith AC, Robinson AJ. MitoMiner, an integrated database for the storage and analysis of mitochondrial proteomics data. Mol Cell Proteomics. 2009;8(6):1324–1337.
   PubMed Web of Science ®Google Scholar
• Johnson MD, Yu L-R, Conrads TP, et al. The proteomics of neurodegeneration. Am J Pharmacogenomics. 2005;5(4):259–270.
   PubMedGoogle Scholar
• Moreira PI, Zhu X, Wang X, et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta. 2010;1802(1):212–220.
   PubMed Web of Science ®Google Scholar
• Pienaar IS, Daniels WMU, Götz J. Neuroproteomics as a promising tool in Parkinson’s disease research. J Neural Transm. 2008;115(10):1413–1430.
   PubMed Web of Science ®Google Scholar
• Butterfield DA. The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic Biol Med. 2014;74:157–174.
   PubMed Web of Science ®Google Scholar
• Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453–62.
   PubMed Web of Science ®Google Scholar
• Ghesquière B, Gevaert K. Proteomics methods to study methionine oxidation. Mass Spectrom Rev. 2014;33(2):147–156.
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Aksenova M, et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part 1: creatine kinase bb, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 2002;33:562–571.
   PubMed Web of Science ®Google Scholar
• Celi P, Gabai G. Oxidant/antioxidant balance in animal nutrition and health: the role of protein oxidation. Front Vet Sci. 2015;2:48.
   PubMed Web of Science ®Google Scholar
• Aksenov M, Aksenova M, Butterfield DA, et al. Oxidative modification of creatine kinase BB in Alzheimer’s disease brain. J Neurochem. 2000;74(6):2520–2527.
   PubMed Web of Science ®Google Scholar
• Martínez A, Portero-Otin M, Pamplona R, et al. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol. 2010;20(2):281–297.
   PubMed Web of Science ®Google Scholar
• Pérez VI, Buffenstein R, Masamsetti V, et al. Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat. Proc Natl Acad Sci U S. 2009;106(9):3059–3064.
   PubMed Web of Science ®Google Scholar
• Rosen H, Klebanoff SJ, Wang Y, et al. Methionine oxidation contributes to bacterial killing by the myeloperoxidase system of neutrophils. Proc Natl Acad Sci U S. 2009;106(44):18686–18691.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease–genotypes, phenotype, and treatments. Science. 1997;275(5300):630–631.
   PubMed Web of Science ®Google Scholar
• Tan L, Schedl P, Song HJ, et al. The Toll–>NFkappaB signaling pathway mediates the neuropathological effects of the human Alzheimer’s Abeta42 polypeptide in drosophila. PLoS One. 2008;3:e3966.
   PubMed Web of Science ®Google Scholar
• Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(8):759–767.
   PubMed Web of Science ®Google Scholar
• Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci. 2001;21(9):3017–3023.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers. 2010;20(Suppl 2):S265–79.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH. Mitochondrial manipulation and the quest for Alzheimer’s treatments. EBioMedicine. 2015;2(4):276–277.
   PubMed Web of Science ®Google Scholar
• Gibson GE, Blass JP, Beal MF, et al. The α-ketoglutarate–dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Mol Neurobiol. 2005;31(1–3):043–064.
   PubMed Web of Science ®Google Scholar
• Kish SJ, Bergeron C, Rajput A, et al. Brain cytochrome oxidase in Alzheimer’s disease. J Neurochem. 1992;59(2):776–779.
   PubMed Web of Science ®Google Scholar
• Parker WD, Mahr NJ, Filley CM, et al. Reduced platelet cytochrome c oxidase activity in Alzheimer’s disease. Neurology. 1994;44(6):1086–1090.
   PubMed Web of Science ®Google Scholar
• Bosetti F, Brizzi F, Barogi S, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease. Neurobiol Aging. 2002;23(3):371–376.
   PubMed Web of Science ®Google Scholar
• Valla J, Schneider L, Niedzielko T, et al. Impaired platelet mitochondrial activity in Alzheimer’s disease and mild cognitive impairment. Mitochondrion. 2006;6(6):323–330.
   PubMed Web of Science ®Google Scholar
• Cho D-H, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates-amyloid-related mitochondrial fission and neuronal injury. Science. 2009;324(5923):102–105.
   PubMed Web of Science ®Google Scholar
• Reddy PH, Reddy TP, Manczak M, et al. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev. 2011;67(1–2):103–118.
   PubMed Web of Science ®Google Scholar
• Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem. 2012;120(3):419–429.
   PubMed Web of Science ®Google Scholar
• Wang X, Su B, Fujioka H, et al. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. Am J Pathol. 2008;173(2):470–482.
   PubMed Web of Science ®Google Scholar
• Manczak M, Anekonda TS, Henson E, et al. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006;15(9):1437–1449.
   PubMed Web of Science ®Google Scholar
• Hardas SS, Sultana R, Clark AM, et al. Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol. 2013;1:80–85.
   PubMed Web of Science ®Google Scholar
• Lynn BC, Wang J, Markesbery WR, et al. Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer’s disease. J Alzheimers. 2010;19(1):325–339.
   PubMed Web of Science ®Google Scholar
• Chou JL, D V S, Thomas N, et al. Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer’s disease. J Proteomics. 2011;74(4):466–479.
   PubMed Web of Science ®Google Scholar
• Lovell MA, Xiong S, Markesbery WR, et al. Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochem Res. 2005;30(1):113–122.
   PubMed Web of Science ®Google Scholar
• Gillardon F, Rist W, Kussmaul L, et al. Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics. 2007;7(4):605–616.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Stadtman E. Protein oxidation processes in aging brain. Adv Cell Ag Geront. 1997;2:161–191.
   Google Scholar
• Pamplona R, Dalfó E, Ayala V, et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem. 2005;280(22):21522–21530.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Boyd-Kimball D, Castegna A. Proteomics in Alzheimer’s disease: insights into potential mechanisms of neurodegeneration. J Neurochem. 2003;86(6):1313–1327.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Gnjec A, Poon HF, et al. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer’s disease: an initial assessment. J. Alzheimers. 2006;10(4):391–397.
   PubMed Web of Science ®Google Scholar
• Castegna A, Thongboonkerd V, Klein JB, et al. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J Neurochem. 2003;85(6):1394–1401.
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Thongboonkerd V, et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem. 2002;82(6):1524–1532.
   PubMed Web of Science ®Google Scholar
• Castegna A, Thongboonkerd V, Klein J, et al. Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins. J Neurochem. 2004;88:1540–1546.
   PubMed Web of Science ®Google Scholar
• Poon HF, Castegna A, Farr SA, et al. Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience. 2004;126:915–926.
   PubMed Web of Science ®Google Scholar
• Triplett JC, Zhang Z, Sultana R, et al. Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson’s disease. J Neurochem. 2015;133(5):750–765.
   PubMed Web of Science ®Google Scholar
• Boyd-Kimball D, Castegna A, Sultana R, et al. Proteomic identification of proteins oxidized by A beta(1-42) in synaptosomes: implications for Alzheimer’s disease. Brain Res. 2005;1044:206–215.
   PubMed Web of Science ®Google Scholar
• Poon HF, Frasier M, Shreve N, et al. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice–a model of familial Parkinson’s disease. Neurobiol Dis. 2005;18(3):492–498.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Poon HF. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer’s disease. Exp Gerontol. 2005;40(10):774–783.
   PubMed Web of Science ®Google Scholar
• Poon HF, Hensley K, Thongboonkerd V, et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice–a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med. 2005;39(4):453–462.
   PubMed Web of Science ®Google Scholar
• Reed T, Perluigi M, Sultana R, et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease. Neurobiol Dis. 2008;30(1):107–120.
   PubMed Web of Science ®Google Scholar
• Sultana R, Boyd-Kimball D, Poon HF, et al. Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging. 2006;27(11):1564–1576.
   PubMed Web of Science ®Google Scholar
• Sultana R, Poon HF, Cai J, et al. Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach. Neurobiol Dis. 2006;22(1):76–87.
   PubMed Web of Science ®Google Scholar
• Shoshan-Barmatz V, Israelson A, Brdiczka D, et al. The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death. Curr Pharm Des. 2006;12(18):2249–2270.
   PubMed Web of Science ®Google Scholar
• Weeber EJ, Levy M, Sampson MJ, et al. The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J Biol Chem. 2002;277(21):18891–18897.
   PubMed Web of Science ®Google Scholar
• Lorenzo HK, Susin SA, Penninger J, et al. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ. 1999;6(6):516–524.
   PubMed Web of Science ®Google Scholar
• Susin SA, Lorenzo HK, Zamzami N, et al. Mitochondrial release of caspase-2 and −9 during the apoptotic process. J Exp Med. 1999;189(2):381–394.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Hardas SS, Lange MLB. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer’s disease: many pathways to neurodegeneration. J Alzheimers. 2010;20(2):369–393.
   PubMed Web of Science ®Google Scholar
• Grimsrud PA, Xie H, Griffin TJ, et al. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem. 2008;283(32):21837–21841.
   PubMed Web of Science ®Google Scholar
• Shiozawa M, Fukutani Y, Arai N, et al. Glyceraldehyde 3-phosphate dehydrogenase and endothelin-1 immunoreactivity is associated with cerebral white matter damage in dentatorubral-pallidoluysian atrophy. Neuropathology. 2003;23(1):36–43.
   PubMed Web of Science ®Google Scholar
• Carre M. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem. 2002;277(37):33664–33669.
   PubMed Web of Science ®Google Scholar
• Etoh S, Matsui H, Tokuda M, et al. Purification and immunohistochemical study of actin in mitochondrial matrix. Biochem Int. 1990;20(3):599–606.
   PubMedGoogle Scholar
• Schägger H, Ohm TG. Human diseases with defects in oxidative phosphorylation. 2.F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. Eur J Biochem. 1995;227(3):916–921.
   PubMedGoogle Scholar
• Terni B, Boada J, Portero-Otin M, et al. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer’s disease pathology. Brain Pathol. 2010;20(1):222–233.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Lepsverdize E, Chi SL, et al. Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells. Mol Psychiatry. 2008;13(10):953–969.
   PubMed Web of Science ®Google Scholar
• Lemire J, Mailloux RJ, Appanna VD. Mitochondrial lactate dehydrogenase is involved in oxidative-energy metabolism in human astrocytoma cells (CCF-STTG1). PLoS One. 2008;3(2):e1550.
   PubMedGoogle Scholar
• Begcevic I, Kosanam H, Martínez-Morillo E, et al. Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains. Clin Proteomics. 2013;10(1):5.
   PubMedGoogle Scholar
• Sultana R, Baglioni M, Cecchetti R, et al. Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radic Biol Med. 2013;65:595–606.
   PubMed Web of Science ®Google Scholar
• Sultana R, Mecocci P, Mangialasche F, et al. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer’s disease: insights into the role of oxidative stress in Alzheimer’s disease and initial investigations into a potential biomarker for this. J Alzheimers. 2011;24(1):77–84.
   PubMed Web of Science ®Google Scholar
• Robinson DS. Changes in monoamine oxidase and monoamines with human development and aging. Fed Proc. 1975;34(1):103–107.
   PubMedGoogle Scholar
• Veitinger M, Varga B, Guterres SB, et al. Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers? Acta Neuropathol Commun. 2014;2:65.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet. 1989;1(8649):1269.
   PubMed Web of Science ®Google Scholar
• Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem. 1993;61(4):1191–1206.
   PubMed Web of Science ®Google Scholar
• Martinez TN, Greenamyre JT. Toxin models of mitochondrial dysfunction in Parkinson’s disease. Antioxid Redox Signal. 2012;16(9):920–934.
   PubMed Web of Science ®Google Scholar
• Thyagarajan D, Bressman S, Bruno C, et al. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol. 2000;48(5):730–736.
   PubMed Web of Science ®Google Scholar
• Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet. 2004;364(9437):875–882.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shimoji M, Thomas B, et al. Mitochondrial localization of the Parkinson’s disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet. 2005;14(14):2063–2073.
   PubMed Web of Science ®Google Scholar
• Bonifati V. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2002;299(5604):256–259.
   PubMed Web of Science ®Google Scholar
• Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res. 2001;35(6):885–893.
   PubMed Web of Science ®Google Scholar
• Canet-Avilés RM, Wilson MA, Miller DW, et al. The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S. 2004;101(24):9103–9108.
   PubMed Web of Science ®Google Scholar
• Ferrer I, Perez E, Dalfó E, et al. Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson’s disease. Neurosci Lett. 2007;415(3):205–209.
   PubMed Web of Science ®Google Scholar
• van Dijk KD, Teunissen CE, Drukarch B, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson’s disease: a pathogenetically based approach. Neurobiol Dis. 2010;39(3):229–241.
   PubMed Web of Science ®Google Scholar
• Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev. 2011;91(14):1161–1218.
   PubMed Web of Science ®Google Scholar
• Abou-Sleiman PM, Muqit MMK, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci. 2006;7(3):207–219.
   PubMed Web of Science ®Google Scholar
• Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet. 2005;14(15):2099–2111.
   PubMed Web of Science ®Google Scholar
• Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet (London, England). 2005;365(9457):415–416.
   PubMed Web of Science ®Google Scholar
• West AB, Moore DJ, Biskup S, et al. Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S. 2005;102(46):16842–16847.
   PubMed Web of Science ®Google Scholar
• Gloeckner CJ, Kinkl N, Schumacher A, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet. 2006;15(2):223–232.
   PubMed Web of Science ®Google Scholar
• Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S. 2005;102(51):18676–18681.
   PubMed Web of Science ®Google Scholar
• Pienaar IS, Dexter DT, Burkhard PR. Mitochondrial proteomics as a selective tool for unraveling Parkinson’s disease pathogenesis. Expert Rev Proteomics. 2010;7(2):205–226.
   PubMed Web of Science ®Google Scholar
• Basso M, Giraudo S, Corpillo D, et al. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics. 2004;4(12):3943–3952.
   PubMed Web of Science ®Google Scholar
• Trojanowski JQ, Lee VM-Y. Aggregation of neurofilament and α-synuclein proteins in lewy bodies. Arch Neurol. 1998;55(2):151.
   PubMedGoogle Scholar
• Chiasson K, Lahaie-Collins V, Bournival J, et al. Oxidative stress and 17-alpha- and 17-beta-estradiol modulate neurofilaments differently. J Mol Neurosci. 2006;30(3):297–310.
   PubMed Web of Science ®Google Scholar
• Werner CJ, Heyny-von Haussen R, Mall G, et al. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci. 2008;6:8.
   PubMed Web of Science ®Google Scholar
• Dalfó E, Portero-Otín M, Ayala V, et al. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol. 2005;64(9):816–830.
   PubMed Web of Science ®Google Scholar
• Jin J, Meredith GE, Chen L, et al. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson’s disease. Brain Res Mol Brain Res. 2005;134(1):119–138.
   PubMedGoogle Scholar
• Zhou Y, Gu G, Goodlett DR, et al. Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem. 2004;279(37):39155–39164.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang Y, Kovacs M, et al. Microglial activation induced by neurodegeneration: a proteomic analysis. Mol Cell Proteomics. 2005;4(10):1471–1479.
   PubMed Web of Science ®Google Scholar
• Kaul SC, Wadhwa R, Komatsu Y, et al. On the cytosolic and perinuclear mortalin: an insight by heat shock. Biochem Biophys Res Commun. 1993;193(1):348–355.
   PubMed Web of Science ®Google Scholar
• Londono C, Osorio C, Gama V, et al. Mortalin, apoptosis, and neurodegeneration. Biomolecules. 2012;2(4):143–164.
   PubMedGoogle Scholar
• Osorio C, Sullivan PM, He DN, et al. Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice. Neurobiol Aging. 2007;28(12):1853–1862.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Di Domenico F, Swomley AM, et al. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down’s syndrome and Alzheimer’s disease brain. Biochem J. 2014;463(2):177–189.
   PubMed Web of Science ®Google Scholar
• De Iuliis A, Grigoletto J, Recchia A, et al. A proteomic approach in the study of an animal model of Parkinson’s disease. Clin Chim Acta. 2005;357(2):202–209.
   PubMed Web of Science ®Google Scholar
• Spencer JPE, Jenner P, Daniel SE, et al. Conjugates of catecholamines with cysteine and GSH in Parkinson’s disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem. 2002;71(5):2112–2122.
   Google Scholar
• Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson’s disease. J Neurochem. 1999;73(3):1127–1137.
   PubMed Web of Science ®Google Scholar
• Van Laar VS, Dukes AA, Cascio M, et al. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis. 2008;29(3):477–489.
   PubMed Web of Science ®Google Scholar
• Alberio T, Lopiano L, Fasano M. Cellular models to investigate biochemical pathways in Parkinson’s disease. Febs J. 2012;279(7):1146–1155.
   PubMed Web of Science ®Google Scholar
• Alberio T, Bondi H, Colombo F, et al. Mitochondrial proteomics investigation of a cellular model of impaired dopamine homeostasis, an early step in Parkinson’s disease pathogenesis. Mol Biosyst. 2014;10(6):1332–1344.
   PubMed Web of Science ®Google Scholar
• Artal-Sanz M, Tavernarakis N. Prohibitin and mitochondrial biology. Trends Endocrinol Metab. 2009;20(8):394–401.
   PubMed Web of Science ®Google Scholar
• Martinelli P, Rugarli EI. Emerging roles of mitochondrial proteases in neurodegeneration. Biochim Biophys Acta. 2010;1797(1):1–10.
   PubMed Web of Science ®Google Scholar
• Greene AW, Grenier K, Aguileta MA, et al. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. EMBO Rep. 2012;13(4):378–385.
   PubMed Web of Science ®Google Scholar
• Arbuzova S, Cuckle H, Mueller R, et al. Familial Down syndrome: evidence supporting cytoplasmic inheritance. Clin Genet. 2001;60(6):456–462.
   PubMed Web of Science ®Google Scholar
• Perluigi M, Di Domenico F, Buttterfield DA. Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin Appl. 2014;8(1–2):73–85.
   PubMed Web of Science ®Google Scholar
• Kim S, Vlkolinsky R, Cairns N. The reduction of NADH: ubiquinone oxidoreductase 24-and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer’s disease. Life Sci. 2001;68:2741–2750.
   PubMed Web of Science ®Google Scholar
• Busciglio J, Pelsman A, Wong C, et al. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down’s syndrome. Neuron. 2002;33:677–688.
   PubMed Web of Science ®Google Scholar
• Helguera P, Seiglie J, Rodriguez J. Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab. 2013;17:132–140.
   PubMed Web of Science ®Google Scholar
• Shukkur EA, Shimohata A, Akagi T, et al. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum Mol Genet. 2006;15(18):2752–2762.
   PubMed Web of Science ®Google Scholar
• Pogribna M, Melnyk S, Pogribny I, et al. Homocysteine metabolism in children with Down syndrome: in vitro modulation. Am J Hum Genet. 2001;69(1):88–95.
   PubMed Web of Science ®Google Scholar
• Agrimi G, Di Noia MA, Marobbio CM, et al. Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial expression, reconstitution, functional characterization and tissue distribution. Biochem J. 2004;379:183–190.
   PubMed Web of Science ®Google Scholar
• Infantino V, Castegna A, Iacobazzi F, et al. Impairment of methyl cycle affects mitochondrial methyl availability and glutathione level in Down’s syndrome. Mol Genet Metab. 2011;102(3):378–382.
   PubMed Web of Science ®Google Scholar
• Castegna A, Iacobazzi V, Infantino V. The mitochondrial side of epigenetics. Physiol Genomics. 2015;47(8):299–307.
   PubMed Web of Science ®Google Scholar
• Iacobazzi V, Castegna A, Infantino V, et al. Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool. Mol Genet Metab. 2013;110(1–2):25–34.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, Coccia R, Cocciolo A, et al. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer’s disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta. 2013;1832(8):1249–1259.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, Pupo G, Tramutola A, et al. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic Biol Med. 2014;71:270–280.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Gu L, Di Domenico F, et al. Mass spectrometry and redox proteomics: applications in disease. Mass Spectrom Rev. 2014;33(4):277–301.
   PubMed Web of Science ®Google Scholar
• Fu Y, Yi Z, Yan Y, et al. Proteomic analysis of mitochondrial proteins in hydroxycamptothecin-treated SMMC-7721 cells. Zhonghua Gan Zang Bing Za Zhi. 2007;15(8):572–576.
   PubMedGoogle Scholar
• Görg A, Obermaier C, Boguth G, et al. Very alkaline immobilized pH gradients for two-dimensional electrophoresis of ribosomal and nuclear proteins. Electrophoresis. 1997;18(3–4):328–337.
   PubMed Web of Science ®Google Scholar
• Flatmark T. On the heterogeneity of beef heart cytochrome c. II. Some physico-chemical properties of the main subfractions (Cy I-Cy 3). Acta Chem Scand. 1966;20(6):1476–1486.
   PubMedGoogle Scholar
• Jiang Y, Wang X. Comparative mitochondrial proteomics: perspective in human diseases. J Hematol Oncol. 2012;5(1):11.
   PubMed Web of Science ®Google Scholar
• White MY, Brown DA, Sheng S, et al. Parallel proteomics to improve coverage and confidence in the partially annotated Oryctolagus cuniculus mitochondrial proteome. Mol Cell Proteomics. 2011;10(2):M110.004291.
   Web of Science ®Google Scholar
• Nesvizhskii AI, Aebersold R. Interpretation of shotgun proteomic data: the protein inference problem. Mol Cell Proteomics. 2005;4(10):1419–1440.
   PubMed Web of Science ®Google Scholar
• Brandon MC, Lott MT, Nguyen KC, et al. MITOMAP: a human mitochondrial genome database–2004 update. Nucleic Acids Res. 2005;33:D611–3.
   PubMed Web of Science ®Google Scholar
• Ingman M, Gyllensten U. mtDB: human mitochondrial genome database, a resource for population genetics and medical sciences. Nucleic Acids Res. 2006;34:D749–51.
   PubMed Web of Science ®Google Scholar
• Prokisch H, Andreoli C, Ahting U, et al. MitoP2: the mitochondrial proteome database–now including mouse data. Nucleic Acids Res. 2006;34:D705–11.
   PubMed Web of Science ®Google Scholar
• Thiede B, Rudel T. Proteome analysis of apoptotic cells. Mass Spectrom Rev. 2004;23(5):333–349.
   PubMed Web of Science ®Google Scholar
• Smith DJ. Mitochondrial dysfunction in mouse models of Parkinson’s disease revealed by transcriptomics and proteomics. J Bioenerg Biomembr. 2009;41(6):487–491.
   PubMed Web of Science ®Google Scholar
• Graves PR, Haystead TAJ. A functional proteomics approach to signal transduction. Recent Prog Horm Res. 2003;58:1–24.
   PubMedGoogle Scholar
• Zellner M, Baureder M, Rappold E, et al. Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer’s disease but not in non-demented Parkinson’s disease patients. J Proteomics. 2012;75(7):2080–2092.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, Coccia R, Butterfield DA, et al. Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim Biophys Acta. 2011;1814(12):1785–1795.
   PubMed Web of Science ®Google Scholar
• Kim M-R, Kim C-W. Human blood plasma preparation for two-dimensional gel electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;849(1–2):203–210.
   PubMed Web of Science ®Google Scholar
• Zolg W. The proteomic search for diagnostic biomarkers: lost in translation? Mol Cell Proteomics. 2006;5(10):1720–1726.
   PubMed Web of Science ®Google Scholar
• Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2008;1782(10):549–558.
   PubMed Web of Science ®Google Scholar